Anti-estrogen resistant cell lines from Ximbio

 

We're pleased to send you our latest Ximbio product update and to announce the availability of 27 new anti-estrogen resistant breast cancer cell lines for licence from the laboratory of Dr Anne Lykkesfeldt at the Danish Cancer Society.

 

Bekaempelse

Dr Lykkesfeldt has developed and characterised through a series of publications a number of subtypes of parental cell lines MCF-7 and T47D that demonstrate resistance to hormone-dependent breast cancer treatments, in both first-line (tamoxifen or aromatase) and second-line (fulvestrant) application. These cell lines offer utility for developing novel predicative biomarkers for therapy response and to provide a better understanding of the underlying molecular mechanisms of resistance, supporting new drug discovery.

Both parental cell lines are dependent on estrogen for growth and as a result the estrogen receptor (ER) has become a key target for clinical therapies. Given that 80% of all breast cancer cases are ER positive, the primary clinical treatment relies on the inactivation of this receptor with drugs such as tamoxifen, aromatase inhibitors and fulvestrant. However, a wide spread problem for healthcare professionals is that a number of patients will not respond to these drugs or go on to develop resistance.

 

The table below details 12 of the key cell lines together with their drug resistance (where applicable) and a number of publications where they have been applied. The full portfolio of 27 resistant and 3 parental cell lines can be accessed here

 


Resistance type: None


MCF-7/S0.5 Cell line*

Briand et al. 1984. PMID: 6362856
Lykkesfeldt et al. 1989. PMID: 2744230

MCF7/S9 Cell line**

Briand and Lykkesfeldt. 1986. PMID: 3513694
Jensen et al. 2003. PMID: 12732292




Resistance type: Fulvestrant


MCF-7/164R-1 Cell line

Frogne et al. 2009. PMID: 18409071
Madsen et al. 1997. PMID: 9044830

MCF-7/182R-1 Cell line

Frogne et al. 2009. PMID: 18409071
Thrane et al. 2014. PMID: 25362855



 

Resistance type: Tamoxifen


MCF-7/TAMR-4 Cell line

Thrane et al. 2013. PMID: 23609470
Elias et al. 2015. PMID: 24882577




Resistance type: Exemestane


MCF7/ExeR1 Cell line

Hole et al. 2015. PMID: 25667100
Hole et al. 2015. PMID: 25625755




Resistance type: Anastrozole


MCF7/AnaR1 Cell line

Hole et al. 2015. PMID: 25667100
Hole et al. 2015. PMID: 25625755



 

Resistance type: Letrozole


MCF7/LetR1 Cell line

Hole et al. 2015. PMID: 25667100
Hole et al. 2015. PMID: 25625755



 

Resistance type: None


T47D/S5 Cell line+

Kirkegaard et al. 2014. PMID: 24513268
Larsen et al. 2015. PMID: 25706943
Larsen et al. 2015. PMID: 25885472

T47D/S2 Cell line++

Thrane et al. 2014. PMID: 25362855
Larsen et al. 2015. PMID: 25706943
Larsen et al. 2015. PMID: 25885472



 

Resistance type: Tamoxifen


T47D/TR-1 Cell line

Thrane et al. 2014. PMID: 25362855
Larsen et al. 2015. PMID: 25706943
Larsen et al. 2015 PMID: 25885472



 

Resistance type: Fulvestrant


T47D-182R1 Cell line

Kirkegaard et al. 2014. PMID: 24513268
Larsen et al. 2015. PMID: 25706943
Larsen et al. 2015. PMID: 25885472



 

* adapted for growth in 0.5% fetal calf serum
** long-term estrogen-deprived cell line grown in serum-free medium
+ optimised for culturing in the presence of 5% fetal calf serum
++ optimised for culturing in the presence of 2% fetal calf serum